Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2

Breast cancers that express hormonal receptors (HR) and HER2 display resistance to targeted therapy. Tumor-promotional signaling from the HER2 and estrogen receptor (ER) pathways converges at the cyclin D1 and cyclin-dependent kinases (CDK) 4 and 6 complex, which drives cell-cycle progression and de...

Descripción completa

Detalles Bibliográficos
Autores principales: Shagisultanova, Elena, Crump, Lyndsey S., Borakove, Michelle, Hall, Jessica K., Rasti, Aryana R., Harrison, Benjamin A., Kabos, Peter, Lyons, Traci R., Borges, Virginia F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742793/
https://www.ncbi.nlm.nih.gov/pubmed/34728571
http://dx.doi.org/10.1158/1535-7163.MCT-21-0098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742793/
https://www.ncbi.nlm.nih.gov/pubmed/34728571
http://dx.doi.org/10.1158/1535-7163.MCT-21-0098

Ejemplares similares